This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Articles by Andrews, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Right arrow Articles by Andrews, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 242-244, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.242-244.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Single-Dose Pharmacokinetics and Penetration of BMS 284756 into an Inflammatory Exudate

R. Wise, T. Gee, G. Marshall, and J. M. Andrews*

Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom

Received 2 July 2001/ Returned for modification 16 September 2001/ Accepted 10 October 2001

The pharmacokinetics of a single dose of BMS 284756 were determined following oral administration of a 600-mg dose to eight healthy male volunteers. Concentrations of the drug were measured in plasma and a cantharidine-induced inflammatory exudate by a microbiological assay. The mean peak concentration in plasma of 10.4 µg/ml (standard deviation [SD], 1.3 µg/ml) was attained at a mean time of 1.2 h (SD, 0.5 h) after the dose. The penetration into the inflammatory exudate was 82% (SD, 15.7%). A mean peak concentration of 7.2 µg/ml (SD, 2.4 µg/ml) was attained in the inflammatory exudate at 5.3 h (SD, 1.5 h). The elimination half-lives from plasma and inflammatory fluid were 9.8 h (SD, 1.1 h) and 8.5 h (SD, 1.9 h), respectively. The areas under the concentration-time curves for plasma and inflammatory fluid were 96.7 µg · h/ml (SD, 10.3 µg · h/ml) and 77.9 µg · h/ml (SD, 19.2 µg · h/ml), respectively.

* Corresponding author. Mailing address: Department of Medical Microbiology, City Hospital NHS Trust, Dudley Rd., Birmingham B18 7QH, United Kingdom. Phone: 0121 507 4261 or 0121 507 4262. Fax: 0121 551 7763. E-mail: jenny.andrews{at}cityhospbham.wmids.nhs.uk.

Antimicrobial Agents and Chemotherapy, January 2002, p. 242-244, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.242-244.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Jones, R. N., Gordon, K. A., Biedenbach, D. J. (2004). Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study. J Antimicrob Chemother 53: 258-265 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2004). Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci. Antimicrob. Agents Chemother. 48: 86-92 [Abstract] [Full Text]  
  • Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
  • Pankuch, G. A., Jacobs, M. R., Appelbaum, P. C. (2003). Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms. Antimicrob. Agents Chemother. 47: 1140-1142 [Abstract] [Full Text]  
  • Andrews, J., Honeybourne, D., Jevons, G., Boyce, M., Wise, R., Bello, A., Gajjar, D. (2003). Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 51: 727-730 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»